+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030- Product Image
Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030- Product Image
New

Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • PDF Icon

    Report

  • 185 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5941796
Free Webex Call
10% Free customization
Description Jump to:

Hospitals & Clinics is the fastest growing segment, North America is the largest market globally

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Myasthenia Gravis Treatment Market, valued at USD 2.32 Billion in 2024, is projected to experience a CAGR of 7.44% to reach USD 3.57 Billion by 2030. Myasthenia Gravis treatment encompasses pharmaceutical interventions designed to manage this chronic autoimmune neuromuscular disorder, characterized by varying degrees of skeletal muscle weakness and fatigue resulting from impaired nerve-muscle communication. Market growth is primarily driven by the increasing prevalence of the condition globally and enhanced diagnostic capabilities that lead to earlier detection.

Key Market Drivers

Rising global prevalence of Myasthenia Gravis significantly fuels the demand for effective treatments. The increasing number of diagnosed cases worldwide broadens the patient pool requiring chronic disease management, necessitating a wider array of therapeutic options and greater accessibility to existing ones. This trend is driven by improved diagnostic capabilities and enhanced disease awareness among healthcare professionals. For instance, according to a systematic review published in Neuroepidemiology, in October 2024, the mean prevalence rate of Myasthenia Gravis increased from 97.5 cases per million person-years during 1967-2007 to 220.1 cases per million person-years in the 2008-2022 timeframe.

Key Market Challenges

The substantial cost associated with advanced therapies, particularly biologics, presents a significant impediment to the growth of the Global Myasthenia Gravis Treatment Market. These high expenditures directly constrain patient access and adoption, especially in regions with developing healthcare infrastructure or stringent reimbursement policies. Healthcare systems and individual patients often struggle to absorb the ongoing financial burden of these advanced treatments, leading to delays in initiation or discontinuation of therapy.

Key Market Trends

The global Myasthenia Gravis treatment market is significantly influenced by the expansion of personalized medicine approaches. This trend emphasizes tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all strategy to improve efficacy and minimize adverse effects. The increasing understanding of disease heterogeneity and the identification of specific biomarkers are crucial to this evolution. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) 2024 Special 301 Submission, PhRMA member companies invested nearly $101 billion in research and development (R&D) in 2022 alone, underscoring the extensive financial commitment towards innovative and personalized therapeutic solutions.

Key Market Players Profiled:

  • Alexion Pharmaceutical Inc.
  • Grifols International, S.A.
  • Avadel Pharmaceuticals, Plc.
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.

Report Scope:

In this report, the Global Myasthenia Gravis Treatment Market has been segmented into the following categories:

By Treatment Type:

  • CholinesteraseInhibitors
  • Chronic Immunomodulators
  • Monoclonal Antibodies
  • Rapid Immunotherapies
  • Thymectomy
  • Others

By End use:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myasthenia Gravis Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:
  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Myasthenia Gravis Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (CholinesteraseInhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
5.2.2. By End use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Myasthenia Gravis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By End use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Myasthenia Gravis Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By End use
6.3.2. Canada Myasthenia Gravis Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By End use
6.3.3. Mexico Myasthenia Gravis Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By End use
7. Europe Myasthenia Gravis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By End use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Myasthenia Gravis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By End use
7.3.2. France Myasthenia Gravis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By End use
7.3.3. United Kingdom Myasthenia Gravis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By End use
7.3.4. Italy Myasthenia Gravis Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By End use
7.3.5. Spain Myasthenia Gravis Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By End use
8. Asia Pacific Myasthenia Gravis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By End use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Myasthenia Gravis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By End use
8.3.2. India Myasthenia Gravis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By End use
8.3.3. Japan Myasthenia Gravis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By End use
8.3.4. South Korea Myasthenia Gravis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By End use
8.3.5. Australia Myasthenia Gravis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By End use
9. Middle East & Africa Myasthenia Gravis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By End use
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Myasthenia Gravis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By End use
9.3.2. UAE Myasthenia Gravis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By End use
9.3.3. South Africa Myasthenia Gravis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By End use
10. South America Myasthenia Gravis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By End use
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Myasthenia Gravis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By End use
10.3.2. Colombia Myasthenia Gravis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By End use
10.3.3. Argentina Myasthenia Gravis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By End use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Myasthenia Gravis Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Alexion Pharmaceutical Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Grifols International, S.A.
15.3. Avadel Pharmaceuticals, Plc.
15.4. Novartis AG
15.5. Pfizer, Inc.
15.6. AbbVie Inc.
15.7. F. Hoffmann-La Roche Ltd.
15.8. GlaxoSmithKline plc.
15.9. Bausch Health Companies Inc.
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

  • Alexion Pharmaceutical Inc.
  • Grifols International, S.A.
  • Avadel Pharmaceuticals, Plc.
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedNovember 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.32 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.57 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Myasthenia Gravis Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Myasthenia Gravis Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 230 Pages
  • Global
From
Myasthenia Gravis- Pipeline Insight, 2025 - Product Image

Myasthenia Gravis- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Generalized Myasthenia Gravis (gMG) - Pipeline Insight, 2025 - Product Image

Generalized Myasthenia Gravis (gMG) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Myasthenia Gravis Treatment Market Report 2025 - Product Image

Myasthenia Gravis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.